bluebird bio, Inc. (0HOH.L)
USD 9.28
(33.91%)
USD 9.28
(33.91%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -235.04 Million | -352.95 Million | -635.63 Million | -470.35 Million | -564.38 Million | -413.42 Million |
| Net Income | -211.91 Million | -266.57 Million | -819.37 Million | -618.69 Million | -789.6 Million | -555.62 Million |
| Depreciation & Amortization | 28.52 Million | 5 Million | 19.64 Million | 19.35 Million | 17.43 Million | 17.15 Million |
| Deferred income taxes | - | - | 568 Thousand | 7.21 Million | 9.29 Million | -2.15 Million |
| Stock-based compensation | 19.42 Million | 35.18 Million | 127.91 Million | 156.63 Million | 160.62 Million | 110.83 Million |
| Change in working capital | -49.72 Million | -39.12 Million | 17.98 Million | -28.85 Million | 46.11 Million | 19.24 Million |
| Other non-cash items | -36.89 Million | -87.44 Million | 17.62 Million | -6.01 Million | -8.25 Million | -2.88 Million |
| Investing Cash Flow | 154.95 Million | 250.45 Million | 562.55 Million | -84.34 Million | 507.8 Million | -679.43 Million |
| Investments in PPE | -9.05 Million | -13.2 Million | -23 Million | -28.98 Million | -76.25 Million | -55.73 Million |
| Acquisitions | - | - | 8.5 Million | 55.35 Million | 5.22 Million | - |
| Investment purchases | -43.29 Million | - | -451.39 Million | -1 Billion | -756.57 Million | -1.51 Billion |
| Sales/Maturities of investments | 114.37 Million | 161.66 Million | 926.65 Million | 948.16 Million | 1.34 Billion | 894.28 Million |
| Other Investing Activities | 92.93 Million | 102 Million | 101.8 Million | -55.35 Million | -5.22 Million | -623.69 Million |
| Financing Cash Flow | 196.24 Million | 54.25 Million | -93.95 Million | 546.71 Million | 21.18 Million | 737.69 Million |
| Debt repayment | -54.36 Million | -25.71 Million | - | -17.38 Million | -9.94 Million | -1.01 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 248.19 Million | 54.23 Million | 80.33 Million | 541.53 Million | 21.18 Million | 703.85 Million |
| Other Financing Activities | 2.41 Million | 25.72 Million | -93.95 Million | 22.55 Million | 9.94 Million | 34.85 Million |
| Accounts receivables | 5.04 Million | - | 32.74 Million | - | - | - |
| Accounts payables | 2.84 Million | -920 Thousand | 9.28 Million | -20.1 Million | 23.6 Million | 3.61 Million |
| Inventory | -36.56 Million | -7.22 Million | -18.44 Million | - | - | - |
| Other working capital | -16 Million | -30.97 Million | -5.59 Million | -8.75 Million | 22.51 Million | 15.62 Million |
| Cash at beginning of period | 158.44 Million | 206.69 Million | 373.72 Million | 381.7 Million | 417.09 Million | 772.26 Million |
| Cash at end of period | 274.59 Million | 158.44 Million | 206.69 Million | 373.72 Million | 381.7 Million | 417.09 Million |
| Capital Expenditure | -9.05 Million | -13.2 Million | -23 Million | -28.98 Million | -76.25 Million | -55.73 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 116.15 Million | -48.24 Million | -167.03 Million | -7.98 Million | -35.39 Million | -355.16 Million |
| Free Cash Flow | -244.1 Million | -366.16 Million | -658.64 Million | -499.33 Million | -640.63 Million | -469.16 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -81.39 Million | -69.8 Million | -88.51 Million | -211.91 Million | -71.73 Million | -72.9 Million |
| Depreciation & Amortization | 16.52 Million | 15.46 Million | 25.4 Million | 28.52 Million | 1.07 Million | 970 Thousand |
| Deferred income taxes | - | - | - | - | 1.39 Million | 3.71 Million |
| Stock-based compensation | 3.2 Million | 3.76 Million | 3.41 Million | 19.42 Million | 4.86 Million | 5.75 Million |
| Change in working capital | -17.2 Million | -29.46 Million | -20.35 Million | -49.72 Million | 2.87 Million | -10.35 Million |
| Other non-cash items | 6.84 Million | 6.05 Million | 56.01 Million | -36.89 Million | -324 Thousand | 106 Thousand |
| Investing Cash Flow | 1.62 Million | -655 Thousand | 3.78 Million | 154.95 Million | 62.08 Million | 6.94 Million |
| Investments in PPE | -59 Thousand | -1.77 Million | -5.21 Million | -9.05 Million | -2.03 Million | -705 Thousand |
| Acquisitions | - | - | - | - | -64.12 Million | - |
| Investment purchases | - | - | - | -43.29 Million | -8.87 Million | -14.8 Million |
| Sales/Maturities of investments | - | - | 9 Million | 114.37 Million | 73 Million | 22.5 Million |
| Other Investing Activities | 1.68 Million | 1.12 Million | - | 92.93 Million | 64.12 Million | -42 Thousand |
| Financing Cash Flow | -6.06 Million | 64.64 Million | 66.27 Million | 196.24 Million | -42 Thousand | -445 Thousand |
| Debt repayment | -26.43 Million | -49.1 Million | - | -54.36 Million | -11.01 Million | -11.48 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | -42 Thousand | -445 Thousand |
| Common Stock Issuance | - | - | 118.12 Million | 248.19 Million | -50 Thousand | -523 Thousand |
| Other Financing Activities | 23.04 Million | 12.87 Million | - | 2.41 Million | 22.12 Million | 23.94 Million |
| Accounts receivables | - | - | - | 5.04 Million | -5.96 Million | 13.72 Million |
| Accounts payables | 11.06 Million | 1.45 Million | 8.62 Million | 2.84 Million | 8.98 Million | -8.32 Million |
| Inventory | -8.54 Million | -7.18 Million | -11.62 Million | -36.56 Million | -8.43 Million | -12.91 Million |
| Other working capital | -19.72 Million | - | - | - | 8.29 Million | -2.85 Million |
| Cash at beginning of period | 263.91 Million | 274.59 Million | 218.36 Million | 158.44 Million | 218.17 Million | 284.39 Million |
| Cash at end of period | 193.21 Million | 263.91 Million | 274.59 Million | 274.59 Million | 218.36 Million | 218.17 Million |
| Capital Expenditure | -59 Thousand | -1.77 Million | -5.21 Million | -9.05 Million | -2.03 Million | -705 Thousand |
| Effect of forex changes on cash | - | - | - | - | 2.25 Million | - |
| Net cash flow / Change in cash | -70.69 Million | -10.68 Million | 56.22 Million | 116.15 Million | 195 Thousand | -66.22 Million |
| Free Cash Flow | -66.31 Million | -76.45 Million | -19.05 Million | -244.1 Million | -63.88 Million | -73.43 Million |
BIOEX
GXI
MKKGY
5821
GEN
7965